Despite the negative financial performance, the substantial capital raise and FDA approval for the pivotal trial could support the company's clinical development. Traders should monitor the progress of the PARADIGM trial and future funding needs, as the company continues to operate at significant losses.
Price Chart
Executive Summary
Anteris Technologies Global Corp. reported its 2025 annual financial results, showing a significant decline in revenue and increased losses year-over-year. Despite these negative financials, the company highlighted key clinical progress, including FDA approval for its pivotal PARADIGM trial and completion of capital raises totaling $320 million, including a strategic investment from Medtronic.
Key Financial Metrics
Key Facts
- Revenue declined 29% year-over-year from $2.703 million to $1.913 million
- Net loss increased 23% year-over-year from $76.291 million to $94.144 million
- Company completed $320 million in capital raises in early 2026, including investment from Medtronic
- FDA granted Investigational Device Exemption (IDE) approval to initiate the PARADIGM trial in the United States
- Net tangible asset backing per share declined from $1.74 in 2024 to ($0.01) in 2025
Financial Impact
Revenue decreased by $790,000 (29%) and net loss increased by $17.853 million (23%) compared to 2024
Risk Factors
- Continuing operating losses and negative cash flow
- Dependence on successful clinical trial outcomes
- Need for additional future funding
- Execution risk in advancing the DurAVR THV program
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-007003 |
| Document: ef20066524_8k.htm | 0001140361-26-007003 |
| Document: ef20066524_ex99-2.htm | 0001140361-26-007003 |
| Document: 0001140361-26-007003-index-headers.html | 0001140361-26-007003 |
| Document: 0001140361-26-007003-index.html | 0001140361-26-007003 |
| Document: 0001140361-26-007003.txt | 0001140361-26-007003 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | Insider Buy | $7.05 | awaiting T+20 | — | $5.78 (−18.01%) |
Oct 1, 2026 25d ago | Insider Buy | $7.71 | awaiting T+20 | — | $5.78 (−25.03%) |
Sep 23, 2026 4w ago | 8-K | $7.62 $6.01 | ▼ −21.13% | ▼ −21.82% | $5.78 (−24.15%) |
Sep 17, 2026 5w ago | 8-K | $8.16 $6.05 | ▼ −25.86% | ▼ −26.06% | $5.78 (−29.17%) |
Sep 16, 2026 5w ago | 3 | $8.37 $6.26 | ▼ −25.21% | ▼ −27.27% | $5.78 (−30.94%) |
Sep 8, 2026 6w ago | 8-K | $8.62 $7.05 | ▼ −18.21% | ▼ −20.18% | $5.78 (−32.95%) |
Aug 14, 2026 10w ago | Institutional Cluster | $9.42 $8.72 | ▼ −7.43% | ▼ −5.91% | $5.78 (−38.64%) |
Aug 11, 2026 10w ago | Press Release | $8.87 $8.30 | ▲ +6.43% | ▲ +4.53% | $5.78 (+34.84%) |
Jul 31, 2026 12w ago | 8-K | $7.84 $8.74 | ▲ +11.48% | ▲ +8.49% | $5.78 (−26.28%) |
Jul 28, 2026 12w ago | Insider Buy | $8.17 $8.89 | ▲ +8.81% | ▲ +5.43% | $5.78 (−29.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers